WRN-mut CRCs were associated with a higher mean tumor mutational burden (TMB) (49 vs. 10.7 mutations/megabase [mut/MB], p < 0.0001) and a higher PD-L1 expression (13% vs. 4%, p < 0.0001) compared to WRN-wt. This evidence concerns the gene WRN and neoplasm.